

Index

- abdominal aorta, 107–8
 abdominal wall
 anatomy
 anterior, 104–6
 external oblique muscle, 105
 femoral triangle and femoral ring, 106
 inguinal canal, 105–6
 internal oblique and transversus abdominis muscles, 105
 posterior, 106–7
 Caesarean section incision and repair, 78–9
 ABG. *See* arterial blood gases
 abruptio, placental, 308
 abscess, 213
 absolute risk (AR), 377
 absorption, drug, 6, 169
 accuracy, diagnostic testing, 65–6
 ACE inhibitors, 180
 acetyl CoA, 251–2
 aciclovir, 56, 150–1, 152
 acid, 21, 22–3
 acid-base balance
 ABG interpretation, 24–7
 ABG measurement, 24
 buffering systems, 23–4, 254–5
 homeostasis, 22–3
 postoperative care data interpretation, 216
 terminology, 21–2
 umbilical cord, 71
 acidophils, 43, 44, 94
 acidosis, 21. *See also* metabolic acidosis
 diabetic ketoacidosis, 254–5, 256
 respiratory, 25–6
 acquired immunity, 310, 312
 antibodies, 313, 317
 APCs, 312
 B cells, 312
 MHC, 312, 315–16
 T cells, 313–14
 vaccination, 313
 acquired Immunodeficiency syndrome (AIDS), 159–60, 161, 162. *See also* human immunodeficiency virus
 acromegaly, 45
 acrosome reaction, 40, 41
 ACTH. *See* adrenocorticotrophic hormone
 active transport, placental, 306–7
 acute fatty liver of pregnancy (AFLP), 69
 adaptation, cellular, 285
 adaptive immunity. *See* acquired immunity
 Addison's disease, 47
 adenine, 318–19, 320
 adenocarcinoma, cervix, 298–9
 adeno-hypophysis, 43, 94
 adenoma, pituitary, 94
 adenomyosis, 293
 adenylyl cyclase, 275–6
 adipose tissue, 248, 249, 255
 adrenal gland, 44
 dysfunction, 46–7
 hormones, 44
 adrenocorticotrophic hormone (ACTH), 43, 44
 AEDs. *See* antiepileptic drugs
 aerobic metabolism, 238–41, 242, 243
 AFLP. *See* acute fatty liver of pregnancy
 agonists, 171, 172
 AIDS. *See* acquired Immunodeficiency syndrome
 aldosterone, 44
 alkali, 21
 alkaline phosphatase, 5, 69
 alkalosis, 21
 metabolic, 22, 26–7
 respiratory, 26, 27
 alkylating agents, 184
 alopecia, 184
 alpha radioimmunotherapy, 370
 ambiguous genitalia, 338
 ambulatory urodynamics, 235
 amenorrhoea, 190–2, 195
 aminoglycosides, 176
 ammonia (NH₃), 23
 amniotic fluid, 13, 14, 15
 ampicillin, 172
 Amsel's criteria, 141
 anaemia, 5–6, 79–80
 anaerobic metabolism, 238, 239, 240, 241
 anaesthesia, 77–8, 94–5
 anal sphincters, 79, 83, 90, 96
 anal triangle, 96–7
 analgesia, 181–2
 androgens, 29, 44, 259, 260, 264
 androstenedione, 262, 263
 anion, 21
 anion gap, 22
 ano-coccygeal ligament, 96
 anogenital warts, 155–6, 157, 158
 ano-rectal junction, 89–90, 96
 antacids, 182–3
 antagonists, 171, 172
 antenatal care, 79
 anaemia, 79–80
 gastric reflux, 80
 hyperemesis gravidarum, 79
 antenatal screening
 congenital infection, 55, 56
 data interpretation, 67, 68
 hepatitis immunology and, 317
 anterior pituitary, 43, 94
 antibiotic-associated diarrhoea, 214
 antibiotics, 171, 173
 anti-tumour, 184
 chlamydial infection treatment, 203
 COC interactions, 198–9
 gonococcal infection treatment, 203
 gonorrhoea resistance, 146, 147, 203
 PID treatment, 202–3
 surgical prophylaxis, 203, 205–7, 211–12
 teratogenesis, 176
 UTI treatment, 204
 vaginal and vulval infection treatment, 203–4
 antibodies
 acquired immunity, 313, 317
 fetal, 317
 fetal protection against maternal, 316
 thyroid, 69, 80
 anticoagulants, 172, 174, 176–7, 317
 anti-D immunoglobulin, 136–7
 antidepressants, 174
 antiemetics, 182
 antiepileptic drugs (AEDs), 6, 80–1, 171, 174, 175–6, 198–9
 antifungals, 203–4, 231

- antigen presenting cells (APCs), 312
 antihypertensive drugs, 80, 179–80
 antimetabolites, 177, 183
 antimuscarinic drugs, 235–6
 anti-oestrogens, 190–2, 195
 antiphospholipid syndrome (APLS), 126, 127
 antiprogesterones, 8–9
 antiretroviral therapy (ART), 159, 160, 162–3, 164–5
 anti-tumour antibiotics, 184
 anus, 90
 APCs. *See* antigen presenting cells
 APGAR scores, 72, 73
 APLS. *See* antiphospholipid syndrome
 apoptosis, 286
 appendix, 88–9
 apposition, 304
 AR. *See* absolute risk
 arachidonic acid, 265
 array comparative genomic hybridization (array CGH), 326–7, 343–5, 346
 ART. *See* antiretroviral therapy
 arterial blood gases (ABG), 3, 4
 acid-base balance
 interpretation of, 24–7
 measurement of, 24
 data interpretation, 66
 arterial disease, 197–8
 arterial supply, pelvis, 92–3
 arterio-venous oxygen gradient, 2
 arthritis, sexually acquired, 145, 146
 aspirin, 181, 317
 atenolol, 179
 atosiban, 180, 278–9
 atrophy, 285
 audit, 386
 augmentation of labour, 81
 autolysis, 286
 autosomal dominant inheritance, 332, 334
 autosomal recessive inheritance, 332, 335
 average, 374
 azithromycin, 147, 148, 203, 205–7
- B cells, 312
 bacteraemia, 210
 bacterial flora, 310
 bacterial infection. *See specific bacterial infections*
 bacterial vaginosis (BV)
 altered vaginal discharge, 141, 144, 145, 230–1
 diagnosis, 140, 141, 144
 management, 141, 144
 microbiology swab results, 72, 73
 pregnancy complications, 145
- balanced reciprocal translocation, 330–1, 332
 barriers, innate immunity, 310
 base, 21
 base excess, 22
 base pairing, 318–19, 320
 basophils, 43, 44, 94, 311
 BBV. *See* blood borne viruses
 benzyl penicillin, 155
 beta-agonists, 9, 180, 181, 277
 beta-blockers, 179–80
 beta-oxidation, fats, 250–1, 252, 253
 bicarbonate (HCO_3^-), 217
 in acid-base balance, 21, 22–3, 254–5
 pregnancy changes in, 3–4
 bile acids, 80
 binary variables, 373–4
 summary statistics for, 376–8
 bioavailability, 169
 biophysics, 350
 ECG, 350–3
 electrosurgery, 363–7
 lasers, 367–8
 microwave energy, 367
 radiotherapy, 368–70
 ultrasound, 353–8
 x-rays, 358–63
 bipolar electrosurgery, 364
 birth, fetal physiology, 19–20
 bladder, 69, 88
 blastocyst, 31, 41–2, 109–10. *See also* implantation
 blinding, clinical trials, 384–5
 blood borne viruses (BBV), 139, 140.
 See also human immunodeficiency virus; viral hepatitis
 blood flow, 2
 disturbances in, 289–91
 fetal, 12–13, 19–20
 renal, 3–4
 blood glucose levels, 241–2, 243, 244
 blood pH, 24, 254–5
 blood pressure, 2. *See also* hypertension
 blood sampling, fetal, 17, 19, 71
 blood tests, 65
 BMD. *See* bone mineral density
 B-mode ultrasound scanning, 354–6
 body fluids, disturbances in, 289–91
 body segment development, 111–12
 bone mineral density (BMD), 360
 bone resorption, 269, 270–1
 bones
 buffer function of, 24
 causes of short long, 348
 fetal skull, 93–4
 thyroid gland function in, 48
 box and whisker plot, 375
 brachytherapy, 369–70
- brain
 development, 14–15
 glucose requirement, 238
 malformations, 349
 BRCA genes, 297–8, 347–9
 breast feeding. *See* lactation
 breast milk
 composition, 7–8, 255, 257
 immunology, 317
 production of, 6–7
 bromocriptine, 7, 84, 192
 buffer, 21
 buffering systems, 23–4, 254–5
 bupivacaine, 181–2
 BV. *See* bacterial vaginosis
- cabergoline, 7, 84, 192, 195
 caecum, 88–9
 Caesarean section, 78–9
 CAH. *See* congenital adrenal hyperplasia
 calcitonin, 48, 269
 calcium, 217
 homeostasis, 269
 calcitonin role, 269
 problems with, 270–1
 PTH role, 269, 270
 vitamin D role, 269, 270
 in signalling cascades, 278–9, 280
 calorie intake, 8
 cancer. *See* gynaecological oncology
 candidiasis. *See* vulvo-vaginal candidiasis
 capacitation, 40, 41
 carbamazepine, 175–6, 198–9
 carbohydrate metabolism
 blood glucose control, 241–2, 243, 244
 in diabetes, 244–5
 glucose metabolism, 238–41, 242, 243
 in pregnancy, 245–6
 in starvation, 243–4
 carbon dioxide, 21, 22–3
 carbon dioxide gas lasers, 367
 carbonic acid, 22–3
 carboplatin, 184
 carboprost, 84, 182
 carcinogens, 298
 carcinoma in-situ, 297
 carcinosarcoma, 299–300
 cardiac cycle, 350, 351
 cardiac output (CO), 1, 2, 12
 cardiogenic shock, 291
 cardiomyopathy, peripartum, 84
 cardiotocography (CTG)
 data interpretation, 70
 fetal monitoring during labour, 16–17, 18
 cardiovascular system, physiology, 1–2, 6, 12–13, 19–20

Index

- case-controlled study, 384
 categorical variables, 373–4. *See also*
 binary variables
 cation, 21
 cavitation, ultrasound, 358
 cefalexin, 204, 205–7
 cefoxitin, 149
 ceftriaxone, 147, 148, 149, 203,
 205–7
 cefuroxime, 205–7
 cell. *See also specific cells*
 decidualization changes, 303
 membrane proteins, 273
 receptors, 273–4, 275
 structure and functions, 272, 273,
 281–4
 cell cycle, 281–4
 cancer biology/pathogenesis, 297
 checkpoints, 281, 283
 phases, 281, 282
 cell signalling, 281–4
 GPCRs, 274–6
 hormones and signal transduction
 mechanisms, 273–4, 275
 signal cascades, 276–7, 278–9,
 280–1
 cellular responses
 adaptation, 285
 body fluid and blood flow
 disturbances, 289–91
 death, 285, 286, 287
 healing, 288–9
 inflammation, 287–8, 289
 injury, 285–6
 cellulitis, 213
 central nervous system (CNS)
 aerobic metabolism, 241, 243
 anatomy, 94–5
 glucose requirement, 238
 meninges, 94–5
 thyroid gland function in, 48
 cephalosporins, 176
 cervical cancer, 184, 298–9
 cervical dilatation, 8–9, 10
 cervical ripening, 8–9
 cervicitis
 chlamydia, 143–6, 148
 gonorrhoea, 146–7, 148
 cervix, 90–1
 anatomy, 91
 cyclical changes in, 33
 neoplasms of, 298–9
 sperm passage through, 40
 cetorelix, 195
 CHC. *See* combined hormonal
 contraception
 checkpoints, cell cycle, 281, 283
 chemical mediators, inflammation,
 287–8
 chemotherapeutic agents
 cell cycle checkpoint manipulation
 by, 281, 283
 gestational trophoblastic neoplasia,
 230
 gynaecological oncology, 183–4
 teratogenesis, 177
 chlamydia
 cervicitis, 143–6, 148
 clinical management, 232
 diagnosis, 140, 145, 148
 extragenital infection, 145
 lymphogranuloma venereum, 145–6
 microbiology swab results, 72, 73
 pathology, 293, 294
 sexually acquired reactive arthritis,
 145, 146
 uncomplicated infection treatment,
 203
 chloramphenicol, 176
 CHM. *See* complete hydatidiform mole
 cholestasis, 5, 69, 80
 cholesterol, 250, 251
 intracellular transport and
 metabolism of, 259–61
 steroid hormone synthesis from,
 259, 260
 choriocarcinoma, 129, 130
 chromosomal abnormalities, 324
 analysis, 325–7, 343–5, 346
 common aneuploidies, 327–30, 331
 definitions, 324–5
 deletions and duplications, 342
 mosaicism, 342–3
 non-invasive prenatal testing, 341–2
 prenatal diagnosis, 335
 raised nuchal translucency with
 normal T13, 342–3, 344
 translocation, 126, 330–1, 332, 333,
 339, 340, 342
 triploidy, 343, 344
 chromosomes, 324
 ciprofloxacin, 147, 203, 205–7
 circulation, fetal, 12–13, 19–20
 cisplatin, 184
 clindamycin, 144, 203–4, 205–7, 230–1
 clinical audit, 386
 clinical management
 antenatal care, 79
 anaemia, 79–80
 gastric reflux, 80
 hyperemesis gravidarum, 79
 clinical skills, 77
 Fraser and Gillick competence, 77
 obstetric history, 77
 contraception, 223–6
 delivery management, 81
 operative vaginal delivery, 83
 perineal trauma, 83
 early pregnancy loss, 226–30
 labour management, 81
 fetal head anatomy, 81, 82
 induction of labour, 81
 obstetric anatomy, 81, 82
 maternal medicine, 80
 epilepsy, 80–1
 gestational diabetes, 80
 hypertension/pre-eclampsia, 80
 obstetric cholestasis, 80
 thyroid disease, 80
 postoperative care, 78
 postpartum problems, 83
 breastfeeding, 84
 peripartum cardiomyopathy, 84
 physiology of postpartum period,
 83
 PPH, 84
 STIs, 230–1, 232, 233
 surgical procedures, 78
 Caesarean section, 78–9
 general surgical principles, 79
 perineal repair, 79
 surgical skills, 77
 anaesthesia in pregnancy, 77–8
 surgical considerations in
 pregnancy, 77
 urogynaecology, 233–7
 clinical significance, 373
 clinical skills
 clinical management, 77
 Fraser and Gillick competence, 77
 obstetric history, 77
 data interpretation, 65
 fluid balance, 65
 routine blood tests, 65
 clinical trials, 383–5
 clomifene, 190
 clonidine, 189
Clostridium difficile-associated
 diarrhoea, 214
 clotrimazole, 143, 144, 203–4, 231
 clotting factors, 6, 70
 CMV. *See* cytomegalovirus
 CNS. *See* central nervous system
 CO. *See* cardiac output
 coagulation system, 6, 70
 co-amoxiclav, 203, 204, 205–7
 COC. *See* combined oral contraceptives
 codeine, 181
 codon, 322
 cohort study, 384
 colon, 89
 combined hormonal contraception
 (CHC), 223
 combined oral contraceptives (COC),
 172, 196–7
 clinical management, 223
 diarrhoea and vomiting with, 198
 drug interactions, 198–9
 missed pill, 198, 223
 reasons to stop immediately, 199

- surgery guidelines, 199
 VTE risk, 197–8
- combined transdermal patch (CTP), 197, 223
- combined vaginal ring, 197, 223
- compensation, acid-base imbalance, 22
- complement, 310–11
- complete hydatidiform mole (CHM), 129–32, 229–30
- complete miscarriage, 125, 128
- complete sex reversal, 337–8
- computed tomography (CT), 361
- condyloma acuminatum, 293
- confidence intervals, 376
- conformal radiotherapy (CRT), 369
- congenital abnormalities
 chromosome analysis, 325–7, 343–5, 346
 high risk pregnancies, 339–41
 non-invasive prenatal testing, 341–2
 raised nuchal translucency with normal T13, 342–3, 344
 single gene disorders, 345–7
 ultrasound abnormalities, 347, 348, 349
- congenital adrenal hyperplasia (CAH), 46–7, 260–1, 338
- congenital infections, 53
 antenatal screening, 55, 56
 clinical features, 55–6, 58, 59, 60, 61
 fetal outcomes, 57–63
 incidence, 57, 60
 infective agents, 53, 54–5
 laboratory investigations, 61–3
 maternal exposure to, 55, 58
 maternal outcomes, 63, 64
 prophylaxis, 56, 57, 58, 72
 risk factors, 60
 transmission, 53–5, 56, 57, 58, 60
 travel-associated, 57
 treatment, 64
- consent, 77
- continuous variables, 373
 summary statistics for, 374–6
- contraception
 clinical management, 223–6
 combined oral contraceptives, 172, 196–9, 223
 emergency, 190, 194, 225–6
 intra-uterine progestogen-only devices, 201, 225
 oral progestogen-only contraceptives, 33, 199–200, 224, 225
 parenteral progestogen-only contraceptives, 200–1, 225
 post-pregnancy, 136
- contractility. *See* myometrial contractility
- contrast agents, 362
- copper intra-uterine devices, 225, 226
- cord blood samples, 71
- corpus luteum, 31, 33, 41–2, 120, 262, 263
- corpus luteum cysts, 294
- corpus uteri, 90–1
- correlation, 380
- cortical reaction, 31, 40
- corticosteroids, 182, 259, 260, 264
- cortisol, 44
- COX enzymes. *See* cyclooxygenase enzymes
- coxa bones, 100
- creatinine, 3–4, 65, 69
- CRT. *See* conformal radiotherapy
- CT. *See* computed tomography
- CTG. *See* cardiotocography
- CTP. *See* combined transdermal patch
- Cushing syndrome, 45, 46
- cyclooxygenase (COX) enzymes, 8–9, 265
- CYP enzymes. *See* cytochrome P450 enzymes
- cystadenofibromas, 295
- cystadenomas, 295
- cystometry, 235
- cysts, ovarian, 294–5
- cytochrome P450 (CYP) enzymes, 261–2, 263
- cytomegalovirus (CMV), 53, 54–5
 antenatal screening, 56
 clinical features, 58, 59, 61
 fetal outcomes, 57–63
 laboratory investigations, 61–3
 maternal exposure to, 58
 risk factors, 60
 transmission, 53–5, 56, 57, 60
 treatment, 64
 vaccination, 56
- cytosine, 318–19, 320
- cytotrophoblast, 306
- daily vitamin requirements, 5
- danazol, 193
- data interpretation, 215
 antenatal care, 67, 68, 69
 clinical skills, 65
 core surgical skills, 66, 67, 68
 delivery management, 71–2, 73
 diagnostic test accuracy, 65–6
 early pregnancy care, 218–19
 gynaecological oncology, 219
 gynaecological problems, 215
 labour management, 70–1
 maternal medicine, 67, 69, 70
 postoperative care, 215–18
 sexual and reproductive health, 72–3
 subfertility, 215, 218,
 surgical procedures, 215
- urogynaecology, 219, 220
- death, cell, 285, 286, 287
- decelerations, CTG, 16–17, 18
- decidua
 immunology, 315
 trophoblast invasion, 305
- decidualization, 303
- deep perineal space, 97
- deletions, chromosome, 342
- delivery
 clinical management, 81, 83
 data interpretation, 71–2, 73
 vaginal, 81, 82, 83, 93–4
- deoxyribose nucleic acid (DNA)
 mitochondrial, 240–1, 243
 molecular biology, 318–19
 replication, 319–20
 sequencing, 323, 346–7
- Depo-Provera®, 200–1
- dermoid cysts, 295, 301
- descriptive studies, 384
- desmopressin, 183, 236
- desogestrel, 189–90, 199
- dexamethasone, 44
- dextropropofol, 181
- DGI. *See* disseminated gonococcal infection
- diabetes insipidus (DI), 45
- diabetes mellitus, 50–1. *See also* gestational diabetes mellitus
 carbohydrate metabolism in, 244–5
 clinical management, 80
 data interpretation, 69
 obesity role in, 252–4
- diabetic ketoacidosis, 254–5, 256
- diagnostic studies, 385
- diagnostic tests, 378
 accuracy, 65–6
 effect, 379–80
 likelihood ratios, 379–80
 negative predictive value, 65, 66, 379
 positive predictive value, 65, 66, 379
 sensitivity, 65, 66, 378–9
 specificity, 65, 66, 147, 378–9
- diaphragm, 107
- diarrhoea, 198, 200, 214
- diathermy. *See* electrosurgery
- dienogest, 197
- diet, 251, 252, 254
- dihydrocodeine, 181
- dihydrotestosterone, 39
- Dinoprostone, 81
- discrete variables, 373
- disorders of sexual development (DSDs), 337–9
- disseminated gonococcal infection (DGI), 146, 147
- distribution, drug, 6, 169
- DNA. *See* deoxyribose nucleic acid
- dopamine agonists, 7, 84
- Doppler ultrasound, 356–7

Index

- Down syndrome, 327–8
 doxorubicin, 184
 doxycycline, 146, 147, 148, 149, 203, 205–7
 drospirenone, 196
 drug absorption, 6, 169
 drug administration, 6
 drug distribution, 6, 169
 drug elimination, 6, 169–70
 drug interactions, 171–2
 contraceptives, 198–9, 200–1
 drug monitoring, 170–1
 drugs. *See also* teratogenesis; *specific drug classes*; *specific drugs*
 cellular targets, 273–4, 275
 FDA pregnancy categories, 174
 fetal pharmacotherapy, 177–8
 pharmacodynamics, 171, 172, 173
 pharmacokinetics, 169–71
 prescription during lactation, 177
 prescription during pregnancy, 172–3, 174
 therapeutic window, 170
 DSDs. *See* disorders of sexual development
 dual energy X-ray absorptiometry (DXA), 360
 duct system development, 118–19
 ductus arteriosus, 12–13, 19–20
 ductus venosus, 12–13, 19–20
 duloxetine, 183, 236
 duplications, chromosome, 342
 DXA. *See* dual energy X-ray absorptiometry
 dydrogesterone, 189–90
 dysmenorrhoea, 183, 190, 192, 193
 early pregnancy. *See also* embryology
 data interpretation, 218–19
 nutrition in, 304
 oxygen tension, 304
 early pregnancy problems. *See also* ectopic pregnancy; gestational trophoblastic disease; miscarriage
 anti-D immunoglobulin
 administration, 136–7
 clinical features and diagnosis, 122–5
 clinical management, 226–30
 EPU role, 121–2
 post-pregnancy contraception, 136
 PUL, 136, 227–9
 early pregnancy unit (EPU), 121–2
 EBM. *See* evidence-based medicine
 EC. *See* emergency contraception
 ECG. *See* electrocardiography
 eclampsia. *See* pre-eclampsia
 ectoderm, 111
 ectopic pregnancy, 91
 clinical features and diagnosis, 133–4
 clinical management, 227–9
 definitions and epidemiology, 132, 133
 follow-up, 135–6
 management, 134–5, 228–9
 ECV. *See* external cephalic version
 Edward syndrome, 328, 329
 ejaculation, 40
 electrocardiography (ECG)
 biophysics, 350–3
 cardiac cycle relationship to, 350, 351
 data interpretation, 66, 68
 features of normal, 352–3
 fetal, 17–19
 planes and electrode placement, 350–2
 pregnancy changes in, 2
 electrolytes, 217
 electronic fetal monitoring, 16–17, 18
 electrosurgery
 biophysics, 363–7
 grounded versus isolated
 electrosurgery systems, 363–4
 low-frequency versus high-frequency currents, 363
 monopolar versus bipolar, 364
 safety of, 366–7
 tissue interactions of electric current, 363–6
 waveform effects, 364–6
 elimination, drug, 6, 169–70
 embolus, 290, 291
 embryology
 adrenal gland, 44
 early, 109
 body segment development, 111–12
 embryonic folding, 112, 113
 first week of development, 109–10
 gastrulation, 111
 implantation, 110–11
 neurulation, 111
 teratogenesis, 112
 gastrointestinal tract, 114–17
 pancreas, 49–50
 pituitary gland, 43
 teratogen effects during
 from 8 weeks to term, 175
 from day 18 to 55, 174, 175
 up to day 17, 174
 thyroid gland, 47–8
 urogenital tracts, 117–19, 337
 embryonic folding, 112, 113
 embryonic nutrition, 304
 emergency contraception (EC), 190, 194, 225–6
 endocervical swab, 72, 73, 231
 endocytosis, placental, 307
 endoderm, 111
 endometrial cancer, 184, 299, 300, 347
 endometrial stromal sarcomas (ESSs), 300
 endometrioma, 294–5
 endometriosis, 193, 195, 293
 endometritis, 214
 endometrium, 32–3, 90–1
 endoscopic surgery, lasers in, 367–8
 energy storage, 248–9, 250
 enteroviruses, 54, 55, 58, 59, 61
 Entonox, 181–2
 enzyme induction, 172, 198–9, 200–1
 enzyme inhibition, 172
 enzymes
 DNA replication, 319–20
 drug interactions, 171, 172
 steroidogenic, 261–2, 263
 epidemiological treatment, 139, 146–7
 epididymis, 36, 37–8
 epidural anaesthesia, 77–8, 94–5
 epidural space, 94–5
 epilepsy, 80–1, 175–6
 epithelial cells, decidualization changes, 303
 EPU. *See* early pregnancy unit
 erection, 39–40
 ergometrine, 84, 182
 ergotamine, 175, 278
 erythromycin, 176, 203, 205–7
 Esmya®. *See* ulipristal
 ESSs. *See* endometrial stromal sarcomas
 estrone, 262, 263
 ethinylestradiol, 196–7
 etonogestrel, 197
 etonogestrel-releasing implants, 200–1, 225
 evidence-based medicine (EBM), 382
 audit, 386
 clinical trials, 383–5
 diagnostic studies, 385
 grading of evidence, 386
 levels of evidence, 386
 quantitative and qualitative research, 382–3
 systematic review and meta-analysis, 385
 validation studies, 385
 Evra®, 197
 EVT. *See* extravillous trophoblast
 excretion, drug, 6, 170
 experimental studies, 383–4
 external cephalic version (ECV), 181
 external genitalia
 ambiguous, 338
 development, 119
 external oblique muscle, 105
 external-beam radiotherapy, 369
 extravillous trophoblast (EVT), 305, 315

- facilitated diffusion, placental, 306
 Fagan's normogram, 379–80, 385
 Fallopian tubes
 anatomy, 91
 damage to, 293, 294
 neoplasms of, 301
 famciclovir, 150–1
 familial cancers, 298
 fat metabolism
 diabetic ketoacidosis, 254–5, 256
 ketogenesis, 251–2, 253, 254
 neonatal, 255, 257
 in obesity, 252–4
 oxidation of fats, 250–1, 252, 253
 roles of fats, 248–9, 250
 in starvation, 251–2, 253, 254
 transport of fats, 250, 251
 FBS. *See* fetal blood sampling
 female reproductive physiology, 28
 cyclical changes in uterus, cervix and
 vagina, 32–3
 dominant follicle selection and
 ovulation, 29–31, 32
 fertilisation, 31
 folliculogenesis, 28–9
 hormonal changes during menstrual
 cycle, 29–31, 32, 120
 oocyte transport to uterus, 31
 ova production and storage, 28
 systemic effects of steroid hormones,
 33
 female reproductive tract
 anatomy, 90–3
 neoplasms of, 298–302
 femoral ring, 106
 femoral triangle, 106
 fentanyl, 181–2
 fertilisation, 31, 40–2
 fertilisation age, 110
 fetal anticonvulsant syndrome, 175–6
 fetal blood sampling (FBS), 17, 19, 71
 fetal growth restriction, 14
 fetal haemoglobin (HbF), 15–16, 306
 fetal head anatomy, 81, 82, 93–4
 fetal heart rate (FHR), 13, 16–17, 18
 fetal hydrops, 347
 fetal immune system, 317
 fetal maternal interfaces, 315
 fetal metabolism, 245–6, 248
 fetal monitoring, during labour, 16–19
 data interpretation, 70–1
 fetal pharmacotherapy, 177–8
 fetal physiology
 cardiovascular, 12–13, 19–20
 gastrointestinal, 14
 haematological, 15–16
 during labour, 16–19
 neurological, 14–15
 renal, 14, 15
 respiratory, 13–14, 20
 transitional changes around birth,
 19–20
 fetal valproate syndrome, 80–1
 fetal vasculature development, 306
 feto-maternal circulation, 120
 fetus, maternal immune response
 evasion by, 315–16
 FEV₁. *See* forced expiratory volume 1
 FHR. *See* fetal heart rate
 fibrinogen, 6
 fibrinolytic system, 6
 fibrocystic breast disease, 193
 fibroids, 294
 filling parameters, 235
 FISH. *See* fluorescent *in situ*
 hybridisation
 fixed acid, 22
 flow-volume curves, 66, 67
 fluconazole, 143, 144, 203–4, 231
 fluid balance
 data interpretation, 65
 disturbances in, 289–91
 fluorescent *in situ* hybridisation
 (FISH), 323, 345, 346
 folic acid, 176
 folinic acid, 230
 follicles, 28
 growth and differentiation of,
 28–9
 selection of dominant, 29–31, 32
 follicular cells, 48, 262, 263
 follicular cysts, 294
 follicular phase, 29–31, 32
 follicular stimulating hormone (FSH),
 28, 29
 hormonal changes during menstrual
 cycle, 30, 31, 32
 secretion and functions, 43, 44
 spermatogenesis, 39
 steroidogenic response, 262,
 263
 folliculogenesis, 28–9
 follitropin, 193
 foramen ovale, 12–13, 19–20
 forced expiratory volume 1 (FEV₁), 3,
 66, 67
 forced vital capacity (FVC), 66, 67
 forceps, 83
 foregut, 114–17
 forest plot, 66, 385
 46XX male, 337, 338
 46XY ambiguous genitalia syndromes,
 338
 46XY female, 337–8
 Fraser principles, 77
 FRC. *See* functional residual capacity
 FSH. *See* follicular stimulating
 hormone
 functional residual capacity (FRC),
 2–3, 66, 67
 fundus, 90–1
 funisitis, 308
 FVC. *See* forced vital capacity
 gadolinium-containing contrast
 agents, 362
 ganirelix, 195
 gaseous exchange, placental, 306
 gastric reflux, 4–5, 80, 182–3
 gastrointestinal tract
 anatomy, 88–90
 chemotherapy side-effects, 184
 development, 114–17
 fetal physiology, 14
 pregnancy physiology, 4–5, 6
 gastrulation, 111
 Gaviscon®, 182–3
 GDM. *See* gestational diabetes mellitus
 Gemeprost, 81
 genes, 324. *See also* single gene
 disorders
 expression, 280–1
 genetic screening and diagnosis, 337
 congenital abnormalities
 chromosome analysis, 325–7,
 343–5, 346
 high risk pregnancies, 339–41
 non-invasive prenatal testing,
 341–2
 raised nuchal translucency with
 normal T13, 342–3, 344
 single gene disorders, 345–7
 ultrasound abnormalities, 347,
 348, 349
 DSDs, 337–9
 gynaecological tumours, 347–9
 infertility and miscarriage, 339,
 340
 genetics
 cancer, 297–8, 347–9
 hydatidiform mole, 130
 obesity, 252–4
 genital infestations, 158–9
 genital lumps, 155–8
 genital tract infection, 72–3
 genital ulceration
 HSV, 150–1, 152
 syphilis, 151–5
 genitalia
 ambiguous, 338
 development, 119
 genomic variation, 324, 325. *See also*
 chromosomal abnormalities;
 single gene disorders
 gentamicin, 203, 204, 205–7
 germ cell tumours, 295, 301
 germ layers, 111
 gestational age, 110, 120–1
 gestational diabetes mellitus (GDM),
 50–1, 69, 80, 246

Index

- gestational trophoblastic disease (GTD), 129, 130, 184, 309
 clinical features and diagnosis, 130
 clinical management, 229–30
 epidemiology, 129–30
 follow-up and prognosis, 132, 230
 genetics, 130
 management, 131, 230
 neoplasia development, 132, 230
 ultrasound diagnosis, 131, 229–30
 gestational trophoblastic neoplasia (GTN), 132, 230
 gestodene, 189–90
 GFR. *See* glomerular filtration rate
 GH. *See* growth hormone
 Gillick competence, 77
 glomerular filtration rate (GFR), 3–4, 6, 69
 glucocorticoids, 44, 259, 260, 264
 gluconeogenesis, 238, 240, 243–4
 glucose levels, blood, 241–2, 243, 244
 glucose metabolism
 aerobic, 238–41, 242, 243
 anaerobic, 238, 239, 240, 241
 glucose tests, 69
 glyceryl trinitrate (GTN), 180
 glycogen, 241–2
 glycolysis, 238, 239, 240, 241
 glycosuria, 69
 gonadal steroids. *See* sex steroids
 gonadorelin analogues, 195
 gonadotrophin-releasing hormone antagonists, 195
 gonadotrophins, 193
 gonads. *See also* ovary; testis
 descent of, 119
 development, 117–19
 gonorrhoea
 antibiotic resistance, 146, 147, 203
 cervicitis, 146–7, 148
 clinical management, 232
 diagnosis, 140, 146, 147, 148
 disseminated infection, 146, 147
 management, 146–7, 148
 microbiology swab results, 72, 73
 pathology, 293, 294
 uncomplicated infection treatment, 203
 G-protein-coupled receptor (GPCR), 274–6
 graft versus host disease, 314
 grafts
 rejection, 314, 317
 types, 314
 granulocytes, 311
 granulomatous inflammation, 288
 granulosa cells, 28–9, 262, 263
 Grave's disease, 69
 griseofulvin, 172
 grounded electrosurgery systems, 363–4
 group B streptococcus, 54, 72, 73
 growth hormone (GH), 43, 44
 GTD. *See* gestational trophoblastic disease
 GTN. *See* gestational trophoblastic neoplasia; glyceryl trinitrate
 guanine, 318–19, 320
 gut, thyroid gland function in, 48
 gynaecological oncology, 183–4. *See also* neoplasia
 data interpretation, 219
 genetic screening and diagnosis, 347–9
 gynaecological pathology. *See also* neoplasia
 non-neoplastic, 293
 endometriosis and adenomyosis, 293
 fibroids, 294
 ovarian cysts, 294–5
 polyps, 293–4
 STIs and tubal damage, 293, 294
 gynaecological problems, data interpretation, 215
 H⁺. *See* proton
 haematology
 chemotherapy side-effects, 184
 data interpretation, 70
 fetal physiology, 15–16
 pregnancy physiology, 5–6
 haematopoiesis, fetal, 15–16
 haemoglobin (Hb), 15–16, 23, 65, 306
 haemolytic disease of newborn, 316, 341–2
 haemorrhage. *See* postpartum haemorrhage
 haemorrhagic disease of newborn, 7–8
 haemorrhoids, 90
 haemostasis, 6
 Hashimoto's thyroiditis, 69
 Hay/Ison criteria, 141
 Hb. *See* haemoglobin
 HbF. *See* fetal haemoglobin
 hCG. *See* human chorionic gonadotrophin
 HCO₃⁻. *See* bicarbonate
 HDL. *See* high-density lipoproteins
 healing
 cellular response, 288–9
 wound, 289
 heart
 aerobic metabolism, 241, 243
 fetal, 12
 heart rate (HR)
 fetal, 13, 16–17, 18
 pregnancy physiology, 1, 2
 heartburn, 4–5, 80, 182–3
 heat, ultrasound, 358
 helicase, 319–20, 321–2
 Henderson-Hasselbalch equation, 24
 heparin, 174, 176–7, 317
 hepatic metabolism, 169–70
 hepatitis. *See* viral hepatitis
 hepatitis A virus, 54–5, 57
 maternal outcome, 63
 sexually transmitted, 163, 166
 vaccination, 57, 163, 166
 hepatitis B virus, 54–5
 antenatal screening, 56
 data interpretation, 72
 investigations, 140
 sexually transmitted, 163–7
 transmission, 54, 55, 57
 vaccination, 57, 72, 166
 hepatitis C virus, 54–5
 investigations, 140
 sexually transmitted, 166, 167
 hepatitis E virus, 54–5, 63
 herpes simplex virus (HSV), 54–5
 clinical features, 58, 59
 clinical management, 233
 congenital infection, 53–5, 56, 58, 59, 60, 64
 diagnosis, 140, 150
 genital ulceration, 150–1, 152
 pregnancy complications, 151, 152
 prophylaxis, 56
 risk factors, 60
 transmission, 53–5, 56, 60, 151, 152
 treatment, 64, 150–1
 high-density lipoproteins (HDL), 250, 251, 259
 high-grade serous carcinoma
 Fallopian tube, 301
 ovarian, 301
 hindgut, 114–15
 hip bones, 100
 HIV. *See* human immunodeficiency virus
 HM. *See* hydatidiform mole
 homeostasis
 acid-base balance, 22–3
 calcium, 269–71
 cell, 285
 hormone receptors
 cell signalling role, 273–4, 275
 membrane proteins, 273
 steroid hormones, 264–5
 hormone replacement therapy (HRT)
 oestrogens, 186–9
 progestogens and progesterone receptor modulators, 189–90, 191, 194
 risks associated with, 186–7, 188
 hormones. *See also* steroid hormones; *specific hormones*
 adipose tissue, 249
 adrenal, 44
 cell signalling role, 273–4, 275

- menstrual cycle changes, 29–31, 32, 120
 normal pregnancy changes, 120
 pancreas, 51
 pituitary, 43, 44, 94
 placenta synthesis of, 307–8
 spermatogenesis control, 39
 thyroid, 48–9
 hPL. *See* human placental lactogen
 HPV. *See* human papillomavirus
 HR. *See* heart rate
 HRT. *See* hormone replacement therapy
 HSD enzymes. *See* hydroxysteroid dehydrogenase enzymes
 HSV. *See* herpes simplex virus
 human chorionic gonadotrophin (hCG), 31, 41–2, 120
 data interpretation in early pregnancy care, 218–19
 ectopic pregnancy diagnosis, 134, 228
 GTD follow-up and prognosis, 132, 230
 placenta synthesis of, 308
 PUL diagnosis, 136
 human immunodeficiency virus (HIV), 159
 aetiology, 159, 160
 antenatal screening, 56
 clinical features, 58, 59
 history, 139
 laboratory investigations, 61–3, 140
 management, 160
 natural history, 159–60, 161, 162
 pregnancy complications, 162–3, 164–5
 pre-test discussions, 161–2
 prophylaxis, 56
 risk factors, 60
 transmission, 54, 55, 160–1
 human menopausal gonadotrophin, 193
 human papillomavirus (HPV), 54–5
 anogenital warts, 155–6, 157, 158
 cervical carcinoma role, 298–9
 clinical features, 61, 155–6
 diagnosis and assessment, 156
 management, 156, 157, 158, 162–3, 164–5
 pregnancy complications, 156
 risk factors, 60
 transmission, 54, 55, 156, 162–3
 vaccination, 57, 155, 298–9
 human placental lactogen (hPL), 80, 308
 humoral immunity, 310–11
 hydatidiform mole (HM), 129–32, 184, 229–30, 309
 hydralazine, 80, 180
 hydrocortisone, 182
 hydronephrosis, 69
 hydro-salpinx, 91
 hydroxysteroid dehydrogenase (HSD) enzymes, 261–2, 263
 hyperadrenalism, 46
 hypercalcaemia, 270
 hyperemesis gravidarum, 69, 79, 182
 hyperglycaemia, 245, 246
 hyperplasia, 281, 285
 endometrial, 299, 300
 hypersensitivity reactions, 315, 317
 hypertension, 80, 179–80. *See also* pre-eclampsia
 hyperthyroidism, 49, 69
 hypertrophy, 285
 hypoadrenalism, 47
 hypocalcaemia, 270
 hypoglycaemia, 241, 244, 245
 hypophyseal arteries, 43, 94
 hypothalamo-pituitary-gonadal axis, 29, 30
 hypothalamus, 94
 hypothesis testing, 372–3
 hypothyroidism, 49, 50, 69, 80
 hypovolaemic shock, 291
 hypoxia
 fetal
 CTG features of, 16–17, 18
 ECG features of, 17–19
 fetal blood sampling features of, 17, 19
 types of, 19
 hysterosalpingography, 359
 IgG, 316, 317
 #iknowmyABGs, 24–7
 iliac arteries, 88, 92–3
 iliac bone, 100–1
 iliacus muscle, 106–7
 ilio-coccygeus, 96
 ilium, 100
 imidazole drugs, 203–4, 231
 imipramine, 183
 imiquimod, 157, 158
 immune cells, decidualization changes, 303
 immune system. *See also* immunology
 development, 15–16
 fetal, 317
 maternal, 317
 immunoglobulin
 acquired immunity, 313, 317
 in breast milk, 8
 fetal, 15–16, 317
 fetal protection against maternal, 316
 placental transport, 307
 immunology
 acquired immunity, 310, 312–14, 315–16, 317
 hypersensitivity reactions, 315, 317
 innate immunity, 310
 pregnancy
 breast milk, 317
 fetal evasion of maternal immune response, 315–16
 fetal immune system, 317
 haemolytic disease of newborn, 316, 341–2
 hepatitis immunology and antenatal screening, 317
 immunological problems to solve in, 315
 maternal fetal interfaces, 315
 maternal immune system, 317
 reproductive immunology in pregnancy disorders, 317
 transplant, 314–15, 317
 immunosuppressive drugs, 317
 immunotherapy, for pregnancy disorders, 317
 implantation, 110–11, 304
 apposition, 304
 attachment, 304
 pre-attachment, 303–4
 imprinting, 334, 342
 IMRT. *See* intensity-modulated radiation therapy
 incomplete miscarriage, 125, 127
 incontinence, 183, 234–6
 independent groups, 380
 indomethacin, 8–9
 induction of labour, 81
 infarction, 290
 placental, 308
 infection, 210. *See also* congenital infections; sexually transmitted infections; surgical site infection
 inflammatory response to, 210
 oncogenic, 298
 postoperative control, 78
 urinary tract, 3–4, 204, 233–4
 inferior hypophyseal artery, 43, 94
 inferior vena cava (IVC), 108
 infertility
 data interpretation, 215, 218,
 drugs used to treat
 anti-oestrogens, 190–2, 195
 gonadotrophin-releasing hormone antagonists, 195
 gonadotrophins, 193
 genetic screening and diagnosis, 339, 340
 male, 35, 339
 infestations, genital, 158–9
 inflammation
 acute, 287–8, 289
 cellular response, 287–8, 289
 chronic, 288, 289
 NF- κ B pathway and, 280–1
 response to infection, 210

Index

- influenza virus, 57, 63
 inguinal canal, 105–6
 inheritance, 332–5, 336
 inherited cancers, 298
 injury, cell, 285–6
 innate immunity, 310–11
 innominate bone, 100
 insulin, 50–1, 80, 171, 174, 244, 245
 insulin resistance, 171, 245, 246, 252–4
 intensity-modulated radiation therapy (IMRT), 369
 intercalating agents, 184
 intermediate lobe, pituitary, 43
 intermittent auscultation, 16
 internal iliac artery, 88, 92–3
 internal oblique muscle, 105
 internal pudendal vessels, 96–7
 internal-beam radiotherapy, 369–70
 interphase, 319–20
 interquartile range (IQR), 375
 intestinal tract. *See* gastrointestinal tract
 intraoperative prevention, SSIs, 212
 intra-uterine devices (IUDs), 201, 225, 226
in-utero infection transmission, 53, 54
 invasion, placenta, 305
 iodine, 48
 ion channels, drugs blocking, 171, 173
 IQR. *See* interquartile range
 iron, 5–6
 iron deficiency anaemia, 5–6, 79–80
 ischial bone, 101
 ischio-anal abscess, 96–7
 ischio-coccygeus, 96
 ischio-rectal fossa, 96–7
 ischium, 100
 isolated electrosurgery systems, 363–4
 itraconazole, 143, 144, 203–4
 IUDs. *See* intra-uterine devices
 IVC. *See* inferior vena cava
- Jarisch-Herxheimer reaction, 154
- karyotyping, 325, 343, 344
 ketogenesis, 251–2, 253, 254
 ketogenic diet, 252, 254
 ketone bodies, 246, 251–2, 253, 254–5, 256
 kidney
 acid-base homeostasis, 22–3
 anatomy, 87
 development, 117–18
 fetal physiology, 14, 15
 pregnancy physiology, 3–4, 6
- labetalol, 80, 179
 labour
 clinical management, 81
 fetal head anatomy, 81, 82
- induction of labour, 81
 obstetric anatomy, 81, 82
 fetal monitoring, 16–19
 data interpretation, 70–1
 pain relief during, 181–2
 physiology, 3
 fetal, 16–19
 onset, myometrial contractility and cervical dilatation, 8–9, 10
 third stage, 8
 preterm, 180, 276–7
 third stage, 8, 182
- lactate
 fetal blood sampling, 71
 production of, 238, 240
 lactate dehydrogenase reaction, 238, 239
- lactation. *See also* breast milk
 antibiotic treatments during, 147
 clinical management, 84
 composition of breast milk, 7–8
 drugs in relation to, 177
 maternal calorie intake requirements, 8
 physiology, 6–8
 pregnancy during, 8
 suckling stimulus, 7
 vitamin daily requirements, 5
- lamotrigine, 175–6, 223
- lasers
 biophysics, 367–8
- last menstrual period (LMP), 120–1
- LCAH. *See* lipid congenital adrenal hyperplasia
- LDL. *See* low density lipoproteins
- leiomyoma, 294
 leiomyosarcoma, 300
- leptin, 249
- levator ani muscle, 96
- levonorgestrel, 189–90, 191, 199, 201, 225, 226
- Leydig cells, 36, 37, 39, 262, 263
- LGV. *See* lymphogranuloma venereum
- LH. *See* luteinising hormone
- lice, pubic, 158–9
- likelihood ratios (LR), 379–80
- limb abnormalities, 348
- lipid congenital adrenal hyperplasia (LCAH), 260–1
- lipoproteins, 250, 251, 259
- Listeria monocytogenes*, 53, 54, 55
- lithium, 171
- liver, 5
 liver disease, 69
- LMP. *See* last menstrual period
- long bones, causes of short, 348
- low density lipoproteins (LDL), 250, 251, 259
- LR. *See* likelihood ratios
- lumbar plexus, 97–8, 106–7
- lumbar puncture, 94–5
- lung development, 13–14
- lung fluid, 13, 20
- lung volume, 2–3
- luteal phase, 29–31, 32
- luteinising hormone (LH), 29
 hormonal changes during menstrual cycle, 30–1, 32
 secretion and functions, 43, 44
 spermatogenesis, 39
 steroidogenic response, 262, 263
- lymphogranuloma venereum (LGV), 145–6
- Maalox®, 182–3
- macrolides, 176
- macronutrients, 250, 255, 257
- macrophages, 311
- magnesium sulphate, 9, 80, 180
- magnetic resonance imaging (MRI), 361–3
- major histocompatibility complex (MHC), 312, 315–16
- malathion, 158, 159
- male reproductive physiology, 35
 ejaculation, 40
 erection, 39–40
 fertilisation, 40–2
 reproductive system, 35–6, 37
 spermatogenesis, 35, 36–9
- malignancy, 295. *See also* neoplasia
- malignant mixed Müllerian tumour, 299–300
- markers, tumour, 298, 299
- maternal fetal interfaces, 315
- maternal immune response, fetal evasion, 315–16
- maternal immune system, 317
- maternal medicine
 clinical management, 80
 epilepsy, 80–1
 gestational diabetes, 80
 hypertension/pre-eclampsia, 80
 obstetric cholestasis, 80
 thyroid disease, 80
- data interpretation, 67
 diabetes, 69
 haematology, 70
 liver disease, 69
 renal disease, 69
 thyroid disease, 69
- maternal mortality ratio (MMR), 69
- maternal mortality statistics, 67, 69
- mature cystic teratomas, 295, 301
- MCAD deficiency, 250–1
- mean, 374
- measles virus, 54–5
 clinical features, 58, 59, 61
 laboratory investigations, 61–2, 63
 risk factors, 60

- transmission, 55, 56, 57, 60
 vaccination, 57, 58
 mechanical index, ultrasound, 358
 meconium, 14
 median, 374–5
 medroxyprogesterone, 189–90, 191, 200–1, 225
 mefenamic acid, 183, 190, 193
 membrane proteins, 273
 Mendelian inheritance, 332–3, 334, 335, 336
 meninges, 94–5
 menopause, 186–7, 188, 189
 menorrhagia, 183, 190, 192, 193
 menstrual cycle
 cervical changes, 33
 hormonal changes, 29–31, 32, 120
 uterine changes, 32–3
 meropenem, 204, 205–7
 mesoderm, 111–12
 mesonephric ducts, 117–19
 meso-salpinx, 91
 mesovarium, 91–2
 meta-analysis, 66, 385
 metabolic acid, 22
 metabolic acidosis, 22
 ABG interpretation, 24–5
 bone mineral dissolution, 24
 causes, 25
 fetal, 17, 19
 metabolic alkalosis, 22, 26–7
 metabolism. *See also* carbohydrate metabolism; fat metabolism
 drugs affecting, 171, 173
 hepatic, 169–70
 neonatal, 255, 257
 thyroid gland function in, 48
 metaplasia, 285
 metastasis, 295, 296–7
 to ovary, 301
 metformin, 80, 202, 254
 methotrexate, 135, 174, 183, 184, 229, 230, 317
 methyl dopa, 80, 179
 methylprednisolone, 182
 metoclopramide, 7, 182
 metronidazole, 141, 143, 144, 147, 149, 203–4, 205–7, 230–1
 MHC. *See* major histocompatibility complex
 microbiology swab, 72, 73, 231
 microbiota, 310
 microdeletion syndromes, 342
 microwave energy, 367
 midgut, 114–17
 mifepristone (RU4A6), 8–9, 128–9, 175
 mineralocorticoids, 44, 259, 260, 264
 Mirena®, 201, 225
 miscarriage
 clinical examination, 226–7
 clinical management, 226–7
 definitions and epidemiology, 125
 genetic screening and diagnosis, 339, 340
 management, 128–9, 227
 recurrent, 125–7, 202, 227, 317
 risk factors, 125, 126
 ultrasound diagnosis, 127–8
 mismatch repair genes, 297–8, 347
 misoprostol, 81, 84, 128–9, 175, 182, 227, 278
 missed miscarriage, 125, 127
 missed pill, 198, 200, 223
 mitochondrial function, 240–1, 243
 mixed urinary incontinence, 234, 236
 MMR. *See* maternal mortality ratio
 mode, 374
 molar pregnancy, 129–32, 184, 229–30, 309
 molecular biology, 318
 DNA, 318–19
 DNA replication, 319–20
 protein synthesis, 321–2
 RNA, 319, 320
 techniques, 322–3
 molluscum contagiosum, 156–8
 monocytes, 311
 monopolar electrosurgery, 364
 monosomy X, 328–30, 331
 mood stabilizers, 171
 morbidly adherent placentation, 309
 morphine, 181–2
 mortality statistics, maternal, 67, 69
 morula, 41–2, 109–10
 mosaicism, chromosome, 342–3
 moxifloxacin, 202–3
 MRI. *See* magnetic resonance imaging
 mucinous cystadenomas, 295
 Mullerian ducts, 118–19, 337
 myometrial contractility
 labour physiology, 8–9, 10
 signalling cascades and, 278, 279
 steroid hormone and prostaglandin coordination of, 266–7
 myometrial quiescence, 266–7, 277, 278
 natural killer cells, 311
 nausea and vomiting, 79, 182, 198, 200
 necrosis, 286, 287
 necrotising fasciitis, 213–14
 negative predictive value, 65, 66, 379
Neisseria gonorrhoea. *See* gonorrhoea
 neonatal metabolism, 255, 257
 neoplasia
 cancer biology/pathogenesis, 297
 cancer genetics, 297–8, 347–9
 characteristics of benign and malignant, 296
 differentiation, 295–6
 of female reproductive tract, 298–302
 GTN, 132, 230
 metastasis, 295, 296–7
 paraneoplastic syndromes, 298, 299
 tumour grade, 295–6
 tumour markers, 298, 299
 tumour nomenclature, 295, 296
 tumour staging, 297
 nephrons, 14
 nerve supply
 pelvis, 97–9
 perineum, 97
 neuro-hypophysis, 43, 94
 neurological system
 chemotherapy side-effects, 184
 fetal physiology, 14–15
 ketogenic diet effects, 252, 254
 neurulation, 111
 Nexplanon®, 200–1, 225
 next generation sequencing (NGS), 346–7
 NF-kB, 280–1
 NGS. *See* next generation sequencing
 NH₃. *See* ammonia
 nifedipine, 80, 173, 179, 180
 NIPT. *See* non-invasive prenatal testing
 testing
 nitrofurantoin, 176, 204, 205–7
 nitrogenous bases, 318–19, 320
 NNT. *See* numbers needed to treat
 nomegestrol, 197
 nominal variables, 373–4
 non-invasive prenatal testing (NIPT), 341–2
 non-parametric data, 380
 non-steroidal anti-inflammatory drugs (NSAIDs), 180, 181, 183, 190, 193
 norelgestromin, 197
 norethisterone, 189–90, 191, 199, 200
 norgestimate, 189–90
 norgestrel, 189–90
 Noristerat®, 200, 225
 notochord, 111
 NSAIDs. *See* non-steroidal anti-inflammatory drugs
 nuchal translucency, 342–3, 344
 nuclear receptors, steroid hormone, 264–5
 nucleotides, 318–19, 320
 numbers needed to treat (NNT), 377
 nutrition
 breast milk composition, 7–8, 255, 257
 calorie intake for breast-feeding, 8
 daily vitamin requirements, 5
 early embryonic, 304
 iron requirements, 5–6

Index

- NuvaRing®, 197
 nystatin, 143
- obesity, 249, 252–4
 observational studies, 384
 obstetric anatomy, 81, 82
 obstetric cholestasis, 5, 69, 80
 obstetric history, 77
 obturator nerve, 98
 odds ratio (OR), 378
 oedema, 287, 289–90
 oestradiol
 cyclical changes in cervix, 33
 cyclical changes in uterus, 32–3
 menstrual cycle changes, 29–31, 32
 in myometrial contractility, 266–7
 oocyte transport to uterus, 31
 production, 262, 263
 spermatogenesis, 39
 oestrogens. *See also* oestradiol
 COCs, 196–7
 hormone replacement therapy, 186–9
 lactation suppression, 6–7, 8
 menstrual cycle changes, 29–31, 32
 osteoporosis role, 270–1
 placenta synthesis of, 307–8
 production, 262, 263
 role in labour, 8–9
 structure and synthesis, 259, 260, 264
 systemic effects, 33
 for urinary incontinence, 235–6
 ofloxacin, 149, 202–3, 205–7
 OGTT. *See* oral glucose tolerance test
 Okazaki fragments, 319–20
 oligomenorrhoea, 190–2, 195
 oligospermia, 40
 omega 3 fatty acids, 248, 257
 oncogenic viruses, 298
 oncology. *See* gynaecological oncology
 ondansetron, 182
 oocyte/ova
 fertilisation, 31, 40–2
 ovulation of, 30–1
 production and storage of, 28
 transport to uterus, 31
 oögonia, 28
 operative vaginal delivery, 83
 opioids, 181
 OR. *See* odds ratio
 oral contraceptives
 COCs, 172, 196–9, 223
 POPs, 33, 199–200, 224, 225
 oral glucose tolerance test (OGTT), 69
 ordinal variables, 373–4
 organelles, 272
 os innominatum, 100
 osteoclasts, 269
 osteomalacia, 270
 osteoporosis, 270–1
 ovarian artery, 88, 93
 ovarian cancer, 184, 301, 347–9
 ovarian cysts, 294–5
 ovarian dermoids, 295, 301
 ovary
 anatomy, 91–2
 descent of, 119
 development, 117–19
 folliculogenesis, 28–9
 hormonal changes during menstrual cycle, 29–31, 32, 120
 ova production and storage, 28
 steroidogenic enzyme expression, 262, 263
 ovulation, 29–31, 32
 oxaloacetate, 251–2
 oxybutynin, 183, 235–6
 oxygen consumption, 2, 3
 oxygen tension, 304
 oxygen transfer, placental, 306
 oxytocin, 94
 labour management, 81
 in myometrial contractility, 8–9, 266–7
 PPH management, 84, 182
 role in lactation, 7
 secretion and functions, 43, 44
 signalling cascades, 278–9, 280
- p values, 372–3
 p53, 297–8
 paclitaxel, 184
 p_aCO₂, 21, 22
 Paget's disease, 301–2
 pain management, 181
 drugs used during labour, 181–2
 dysmenorrhoea, 183, 190, 192, 193
 paired groups, 380
 pancreas, 49–51
 paracetamol, 181
 paramesonephric ducts, 118–19
 parametric data, 380
 paraneoplastic syndromes, 298, 299
 parathyroid hormone (PTH), 269, 270
 parenteral progestogen-only
 contraceptives, 200–1, 225
 partial hydatidiform mole (PHM), 129–32, 229–30
 partograph, 70, 71
 parvovirus B19, 53, 54–5
 clinical features, 58, 59, 61
 fetal outcomes, 60–3
 laboratory investigations, 61–3
 maternal exposure to, 58
 risk factors, 60
 transmission, 53–5, 56, 60
 treatment, 64
 Patau syndrome, 328, 330
 pathology. *See* gynaecological pathology
 PCR. *See* polymerase chain reaction
 pediculosis, 158–9
 pelvic cavity, 102–3
 pelvic diameters, 81, 82
 pelvic floor, 96
 pelvic floor problems, 219, 220
 pelvic girdle anatomy
 components, 100
 differences between male and female, 100
 hip bones, 100
 iliac bone, 100–1
 ischial bone, 101
 pelvic cavity, 102–3
 pubic bone, 101
 sacrum, 100, 101–2
 pelvic inflammatory disease (PID), 147, 149–50, 202–3, 293
 pelvic organ prolapse, 236–7
 pelvic splanchnic nerves, 88, 89–90, 98
 pelvis
 anatomy, 81, 82
 arterial supply, 92–3
 nerve supply, 97–9
 pelvic floor anatomy, 96
 pelvic girdle anatomy, 100–3
 penicillins, 176
 perinatal mortality rate (PNMR), 69
 perineal body, 97
 perineal membrane, 97
 perineal repair, 79
 perineum
 anatomy, 96–7
 nerve supply, 97
 trauma, 83
 peripartum cardiomyopathy, 84
 peripartum infection transmission, 54
 peripheral vascular resistance, 2
 permethrin, 158, 159
 pethidine, 181–2
 PGD. *See* preimplantation genetic diagnosis
 PGH. *See* placental growth hormone
 PGs. *See* prostaglandins
 pH, 21
 blood, 24, 254–5
 fetal blood sampling, 71
 homeostasis, 22–3
 pH scale, 21
 phagocytes, 311
 pharmacodynamics, 171, 172, 173
 pharmacokinetics (Pk), 169–71
 phase I metabolism, 169
 phase II metabolism, 170
 phases, clinical trials, 383
 phenytoin, 172, 175–6, 198–9
 pheochromocytoma, 47
 PHM. *See* partial hydatidiform mole

- phosphate (PO_4^{3-}), 23
 phospholipase A_2 (PLA_2), 265
 PID. *See* pelvic inflammatory disease
 piperacillin, 205–7
 pituitary gland, 43, 94
 dysfunction, 43, 45
 hormones, 43, 44, 94
 hypothalamus interaction with, 94
 Pk. *See* pharmacokinetics
 PL. *See* prolactin
 PLA_2 . *See* phospholipase A_2
 placenta, 303. *See also* implantation
 decidualization, 303
 delivery of, 8
 development, 304
 invasion, 305
 spiral artery remodelling, 305
 trophoblast differentiation, 305
 villous structure, 305–6
 early embryonic nutrition, 304
 functions, 306
 hormone synthesis, 307–8
 transport, 306–7
 IgG crossing of, 317
 immunology, 315
 mature, 306
 oxygen tension in early pregnancy, 304
 pathology, 308–9
 steroidogenic enzyme expression, 262
 umbilical cord, 71, 308
 placental growth hormone (PGH), 308
 placental mosaicism, 342
 placental site trophoblastic tumour (PSTT), 129, 130
 plasma osmolality, 3–4
 plasma proteins, 23
 plasma volume, 1, 2, 6
 platelet count, 5, 6
 PNMR. *See* perinatal mortality rate
 PO_4^{3-} . *See* phosphate
 podophyllotoxin, 157, 158
 polycystic ovary syndrome, 202
 polymerase chain reaction (PCR), 322
 qfPCR, 325–6, 343, 344
 polyps, 293–4
 POPs. *See* progesterone only pills
 positive predictive value (PPV), 65, 66, 379
 posterior pituitary, 43, 94
 post-exposure prophylaxis, 56
 postoperative care
 clinical management, 78
 data interpretation, 215–18
 postoperative prevention, SSIs, 212
 postpartum haemorrhage (PPH), 84, 182
 postpartum problems, clinical
 management, 83
 breastfeeding, 84
 peripartum cardiomyopathy, 84
 physiology of postpartum period, 83
 PPH, 84
 postpartum thyroiditis, 80
 post-pregnancy contraception, 136
 PPH. *See* postpartum haemorrhage
 PPV. *See* positive predictive value
 pre-clinical trials, 383
 pre-eclampsia
 clinical management, 80
 drugs used to treat, 179–80
 fluid balance, 65
 immunotherapy for, 317
 pre-exposure anti-virals, 56
 pregnancy. *See also* early pregnancy
 problems
 antibiotic treatments during, 147
 breast feeding during, 8
 carbohydrate metabolism in, 245–6
 dating of normal, 120–1
 drug prescribing during, 172–3, 174
 feto-maternal circulation
 development, 120
 high risk, 339–41
 hormonal changes in normal, 120
 immunology
 breast milk, 317
 fetal evasion of maternal immune
 response, 315–16
 fetal immune system, 317
 haemolytic disease of newborn,
 316, 341–2
 hepatitis immunology and
 antenatal screening, 317
 immunological problems to solve
 in, 315
 maternal fetal interfaces, 315
 maternal immune system, 317
 reproductive immunology in
 pregnancy disorders, 317
 MRI in, 362
 pharmacokinetics and, 171
 physiology
 cardiovascular system, 1–2, 6
 gastrointestinal tract, 4–5, 6
 haematological system, 5–6
 respiratory system, 2–3, 4
 therapeutic drug administration
 implications, 6
 urinary system, 3–4, 6
 STI complications
 altered vaginal discharge, 143, 145
 genital lumps, 158
 HIV, 162–3, 164–5
 HPV, 156
 HSV, 151, 152
 syphilis, 154–5
 viral hepatitis, 167
 ultrasound features in normal, 121,
 128, 218–19
 pregnancy of unknown location
 (PUL), 136, 227–9
 pregnenolone, 259–60
 preimplantation genetic diagnosis
 (PGD), 335
 pre-menstrual syndrome, 201–2
 prenatal diagnosis, 335. *See also* genetic
 screening and diagnosis
 pre-operative prevention, SSIs, 211
 presenting part, 93–4
 preterm labour (PTL), 180, 276–7
 primary epithelial ovarian carcinomas,
 301
 primary research methods, 382–3
 primitive gut tube
 divisions, 114–15
 morphological and positional
 changes during embryonic
 development, 115–17
 primordial follicles, 28
 growth and differentiation of, 28–9
 selection of dominant, 29–31, 32
 primordial germ cells, 117–18
 prochlorperazine, 182
 progesterone, 3
 cyclical changes in cervix, 33
 cyclical changes in uterus, 32–3
 hormone replacement therapy,
 189–90, 191
 lactation suppression, 6–7, 8
 menstrual cycle changes, 29–31, 32
 myometrial contractility
 suppression, 8–9
 oocyte transport to uterus, 31
 placenta synthesis of, 307, 308
 production, 262, 263
 PUL diagnosis, 136
 systemic effects, 33
 tocolytic function of, 266–7
 progesterone only pills (POP), 33,
 199–200, 224, 225
 progesterone receptor modulators,
 189–90, 191, 194
 progestogen only implants, 200–1,
 225
 progestogen-only contraceptives
 intra-uterine, 201, 225
 parenteral, 200–1, 225
 progestogens
 COCs, 196–7
 hormone replacement therapy,
 189–90, 191, 194
 structure and synthesis, 259, 260,
 264
 prolactin (PL), 6–7, 8, 43, 44, 84
 prolactinoma, 45
 proliferative phase, 32–3

Index

- promethazine, 182
 propiverine, 183
 prostaglandin analogues, 81, 278. *See also* misoprostol
 prostaglandin E₂, 81, 265–6
 prostaglandin F_{2α}, 265–7
 prostaglandins (PGs), 259
 actions, 265–6
 in coordination of myometrial contractility, 266–7
 role in labour, 8–9
 synthesis and metabolism, 265
 protein buffers, 23
 protein synthesis, 321–2
 proton (H⁺), 21, 22–3
 proto-oncogenes, 298
 psoas major, 106–7
 PSTT. *See* placental site trophoblastic tumour
 PTH. *See* parathyroid hormone
 PTL. *See* preterm labour
 pubic bone, 101
 pubic lice, 158–9
 pubic symphysis, 100
 pubis, 100
 pubo-coccygeus, 96
 pudendal block, 78, 101
 pudendal nerve, 96–7, 98–9, 101
 pudendal vessels, 96–7
 PUL. *See* pregnancy of unknown location

 qfPCR, 325–6, 343, 344
 quadratus lumborum, 106–7
 qualitative research, 382
 quantitative research, 382–3
 quantitative variables, 373. *See also* continuous variables
 quinolones, 176

 radiography, biophysics, 358–63
 radioisotope therapy, 369–70
 radiotherapy
 biophysics, 368–70
 MRI simulation, 362
 safety of, 370
 raloxifene, 189
 randomisation, clinical trials, 384
 randomized controlled trial (RCT), 384
 range, 375
 RCT. *See* randomized controlled trial
 real-time B-mode ultrasound
 scanning, 354–6
 receptor-mediated endocytosis, placental, 307
 receptors. *See also* hormone receptors
 cellular, 273–4, 275
 drug, 171, 172
 GPCR, 274–6

 rectum, 89–90
 recurrent candidiasis, 142
 recurrent miscarriage, 125–7, 202, 227, 317
 red cell mass, 1, 2
 regeneration, cellular, 288–9
 rejection, transplant, 314, 317
 relative risk (RR), 377
 relative risk reduction (RRR), 377–8
 renal disease, 69
 renal elimination, 170
 renal function
 acid-base homeostasis, 22–3
 fetal physiology, 14, 15
 pregnancy physiology, 3–4, 6
 repair, cellular, 288–9
 replication, DNA, 319–20
 reproductive health, data
 interpretation, 72–3
 reproductive immunology, 317
 reproductive tract
 development, 117–19, 337
 female, 90–3
 male, 35–6, 37
 research methods, 382–3
 respiratory acidosis, 25–6
 respiratory alkalosis, 26, 27
 respiratory system
 fetal physiology, 13–14, 20
 pregnancy physiology, 2–3, 4
 Rhesus (Rh) antigen, 316, 341–2
 ribavirin, 167
 ribose nucleic acid (RNA), 319, 320
 rickets, 7–8, 270
 rifampicin, 172, 198–9
 risk, 377
 risk of malignancy index (RMI), 219
 ritodrine, 180, 277
 RMI. *See* risk of malignancy index
 RNA. *See* ribose nucleic acid
 RNA polymerase, 321–2
 Robertsonian reciprocal translocation, 330–1, 333
 RR. *See* relative risk
 RRR. *See* relative risk reduction
 RU4A6. *See* mifepristone
 rubella virus, 53, 54–5
 antenatal screening, 55, 56
 clinical features, 58, 59, 61
 fetal outcomes, 60, 61
 laboratory investigations, 61–3
 risk factors, 60
 transmission, 53, 55, 56, 57, 60
 vaccination, 55, 56, 57

 sacral plexus, 98–9
 sacro-iliac joint, 100, 101–2
 sacrum, 100, 101–2
 salpingectomy, 134–5, 229
 salpingitis, 293

 salpingostomy, 134–5, 229
 sample, SD and, 376
 SARA. *See* sexually acquired reactive arthritis
 sarcoidosis, 288
 SAYANA PRESS®, 200–1
 scabies, 158
 screening. *See* antenatal screening; genetic screening and diagnosis
 scrotum, 35
 SD. *See* standard deviation
 second messengers, 274, 275–6
 secondary oocyte, 30–1
 secondary research methods, 382–3
 secretory phase, 32–3
 seizure, eclamptic, 80
 selective oestrogen receptor modulators, 189
 sella turcica, 43
 SEM. *See* standard error of mean
 semen analysis, 215, 218,
 spermatogenesis in, 36, 37, 38
 sensitivity, 65, 66, 378–9
 sepsis
 definition, 210, 211
 management, 212–13
 recognition, 212
 septic shock, 210, 211, 291
 serous carcinoma
 Fallopian tube, 301
 ovarian, 301
 serous cystadenoma, 295
 Sertoli cells, 35–6, 37, 39
 sex cord stromal tumours, 301
 sex steroids, 259, 260. *See also* specific hormones
 sexual health, data interpretation, 72–3
 sexually acquired reactive arthritis (SARA), 145, 146
 sexually transmitted infections (STIs), 139
 altered vaginal discharge, 140–3, 144, 145, 203–4, 230–1
 blood-borne viruses, 159–67
 cervicitis, 143–7, 148
 clinical examination, 139–40
 clinical management, 230–1, 232, 233
 data interpretation, 72–3
 genital infestations, 158–9
 genital lumps, 155–8
 genital ulceration, 150–5
 gynaecological pathology caused by, 293, 294
 history, 139
 investigations, 140, 152–4, 167
 management considerations, 140
 PID, 147, 149–50, 202–3, 293
 Sheehan's syndrome, 45

- shock, 210, 211, 291
 SIDS. *See* sudden infant death syndrome
 sigmoid colon, 89
 signal cascades, 276–7
 myometrial contraction and, 278, 279
 myometrial quiescence and, 277, 278
 NF- κ B, 280–1
 oxytocin and intra-cellular calcium, 278–9, 280
 signal transduction, 273–4, 275. *See also* cell signalling
 single gene disorders, 331–2
 genetic screening and diagnosis, 345–7
 Mendelian inheritance, 332–3, 334, 335, 336
 multifactorial, 334–5
 non-invasive prenatal testing, 341–2
 non-Mendelian inheritance, 333–5
 prenatal diagnosis, 335
 skeletal muscle, 241, 243
 sodium valproate, 80–1, 175–6
 solid-state lasers, 367–8
 sound waves, 353, 354
 specificity, 65, 66, 147, 378–9
 spectinomycin, 147
 speculum examination, 123
 spermatidogenesis, 36–7
 spermatids, 36–7, 38
 spermatocytes, 36–7
 spermatogenesis
 final maturation and storage of spermatozoa, 37–8
 hormonal control of, 39
 stages of, 36–7, 38
 spermatogonia, 36
 spermatozoa
 acrosome reaction, 40, 41
 capacitation of, 40, 41
 ejaculation of, 40
 final maturation and storage of, 37–8
 oocyte fertilisation, 40–2
 production of, 36, 38
 spermogenesis of, 37, 38
 vagina and cervix passage by, 40
 spermogenesis, 37, 38
 spinal anaesthesia, 77–8, 94–5
 spiral arteries
 decidualization changes, 303
 remodelling, 305
 spirometry, 66, 67
 spironolactone, 172
 squamous cell carcinoma
 cervix, 298–9
 vulva, 301–2
 SSI. *See* surgical site infection
 standard deviation (SD), 375–6
 standard error of mean (SEM), 376
 starvation
 carbohydrate metabolism in, 243–4
 fat metabolism in, 251–2, 253, 254
 statistical significance, 373
 statistics, 372
 analytical test selection, 380
 clinical significance versus statistical significance, 373
 correlation, 380
 definition and function of, 372
 diagnostic tests, 378
 effect, 379–80
 likelihood ratios, 379–80
 negative predictive value, 65, 66, 379
 positive predictive value, 65, 66, 379
 sensitivity, 65, 66, 378–9
 specificity, 65, 66, 147, 378–9
 hypothesis testing, 372–3
 p values, 372–3
 summary statistics for binary variables, 376–7
 absolute risk, 377
 NNT, 377
 odds and odds ratio, 378
 relative risk, 377
 relative risk reduction, 377–8
 risk, 377
 summary statistics for continuous variables, 374
 box and whisker plot, 375
 confidence intervals, 376
 IQR, 375
 mean, 374
 median, 374–5
 mode, 374
 range, 375
 SD, 375–6
 SEM, 376
 type I and type II errors, 372–3
 types of variables, 373–4
 STB. *See* syncytiotrophoblast
 steroid hormones, 259
 changes during menstrual cycle, 29–31, 32, 120
 cholesterol transport and metabolism, 259–61
 classification and structures, 259, 260
 in coordination of myometrial contractility, 266–7
 cyclical changes in cervix, 33
 cyclical changes in uterus, 32–3
 metabolism and clearance, 262–4
 nuclear receptor actions of, 264
 oocyte transport to uterus, 31
 spermatogenesis, 39
 steroidogenic enzymes, 261–2, 263
 systemic effects of, 33
 transcriptional regulation by, 264–5
 STIs. *See* sexually transmitted infections
 stomach, 115–17
 stress urinary incontinence, 183, 234, 236
 stroke volume, 1, 2, 12
 stromal cells, 303
 strong acid, 22
 subfertility, data interpretation, 215, 218
 suckling stimulus, 7
 sudden infant death syndrome (SIDS), 250–1
 sulphasalazine, 176
 sulphonamides, 172, 176
 superficial perineal space, 97
 superior hypophyseal artery, 43, 94
 supine hypotensive syndrome, 1–2
 surfactant, lung, 14
 surgical antibiotic prophylaxis, 203, 205–7, 211–12
 surgical procedures
 clinical management, 78
 Caesarean section, 78–9
 general surgical principles, 79
 perineal repair, 79
 data interpretation, 215
 surgical site infection (SSI), 210
 abscess, 213
 antibiotic-associated diarrhoea, 214
 cellulitis, 213
 definition of infection, 210
 definition of sepsis, 210, 211
 endometritis, 214
 inflammatory response, 210
 management, 212–13
 necrotising fasciitis, 213–14
 prevention, 210–12
 recognition, 212
 surgical skills
 clinical management, 77
 anaesthesia in pregnancy, 77–8
 surgical considerations in pregnancy, 77
 data interpretation, 66
 ABG, 66
 ECG, 66, 68
 spirometry, 66, 67
 surgical wounds, 211–12
 suture length to wound length ratio, 78–9
 swab. *See* microbiology swab
 swallowing movements, fetal, 14
 syncytiotrophoblast (STB), 305–6, 315
 Syntocinon, 81, 182
 Syntometrine®, 182
 syphilis
 antenatal screening, 56
 clinical features, 58, 59, 61, 151–2, 153

Index

- syphilis (cont.)
 congenital, 53, 55, 56, 58, 59, 60, 61,
 62–3, 64, 153, 155
 data interpretation, 73
 follow-up, 155
 genital ulceration, 151–5
 Jarisch-Herxheimer reaction, 154
 laboratory investigations, 62–3, 140,
 152–4
 pregnancy complications, 154–5
 risk factors, 60
 transmission, 53, 55, 154–5
 treatment, 64, 154, 155
 systematic review, 385
- T cells, 313–14
 T cytotoxic cells (CD8 positive), 314
 T helper cells (CD4-positive), 314
 T3. *See* tri-iodothyronine
 T4. *See* thyroxine
 tamoxifen, 190, 300
 targeted alpha therapy (TAT), 370
 tazobactam, 205–7
 Tazocin, 204, 205–7
 TCA. *See* trichloroacetic acid
 teicoplanin, 203, 205–7
 teratogenesis, 112, 174
 drug categorisation, 174
 embryonic from day 18 to 55, 174,
 175
 known drugs, 175–7
 post-embryonic from 8 weeks to
 term, 175
 pre-embryonic up to day 17, 174
 sources of information, 175, 177
- terbutaline, 180, 181
 testis, 35–6, 37
 descent, 119
 development, 117–19
 steroidogenic enzyme expression,
 262, 263
 testosterone, 37, 39, 262, 263
 testosterone analogues, 189–90, 191
 tetracyclines, 176
 Th2 shift, 317
 theca cells, 28–9, 262, 263
 therapeutic window, 170
 thermal index, ultrasound, 358
 thiazide diuretics, 180
 third stage, labour, 8, 182
 thoraco-lumbar fascia, 106
 threatened miscarriage, 125, 128
 thrombophilia, 126, 127
 thrombosis, 290
 thrush. *See* vulvo-vaginal candidiasis
 thymine, 318–19
 thyroid axis, 48–9
 thyroid disease, 69, 80
 thyroid gland, 47–8
 dysfunction, 49, 50
 hormones, 48–9
 thyroid stimulating hormone (TSH),
 43, 44, 48–9, 69
 thyrotropin releasing hormone (TRH),
 48–9
 thyroxine (T4), 6, 48–9, 69, 80, 171
 tibolone, 186, 187, 188
 tidal volume (TV), 2–3, 66, 67
 tinidazole, 143, 203–4
 TLC. *See* total lung capacity
 tocolytic agents, 9, 180–1, 266–7, 277,
 278–9
 tolterodine, 183, 235–6
 total lung capacity (TLC), 2–3
 toxicity, drug, 169
Toxoplasma gondii, 53
 antenatal screening, 56
 clinical features, 58, 59, 61
 fetal outcomes, 60, 61
 laboratory investigations, 62–3
 risk factors, 60
 transmission, 53, 55, 60
 treatment, 64
 tranexamic acid, 183, 190, 192
 transabdominal scanning, early
 pregnancy problems, 123–4
 transcription, 321–2
 transcription factors, 321–2
 translation, 322
 translocation, chromosomal, 126,
 330–1, 332, 333, 339, 340, 342
 transplant immunology
 graft types, 314
 graft versus host disease, 314
 immunosuppressive drugs, 317
 rejection, 314, 317
 transvaginal ultrasound (TVS)
 early pregnancy findings, 218, 219
 early pregnancy problems, 123–4,
 133, 134, 228
 pregnancy dating, 120–1
 transversus abdominis muscle, 105
 trauma, perineal, 83
Treponema pallidum. *See* syphilis
 TRH. *See* thyrotropin releasing
 hormone
 triacylglycerol, 248–9
 triazole drugs, 203–4, 231
 trichloroacetic acid (TCA), 157, 158
Trichomonas vaginalis (TV), 72, 73
 altered vaginal discharge, 142–3,
 144, 145, 203–4
 clinical management, 232
 diagnosis, 140, 143, 144
 management, 143, 144
 pregnancy complications, 143,
 145
 tri-iodothyronine (T3), 48–9
 trimethoprim, 204, 205–7
 triplet codon, 322
 triplet repeat expansion, 333–4
 triploidy, 343, 344
 trisomy 13, 328, 330
 trisomy 18, 328, 329
 trisomy 21, 327–8
 trophoblast
 cell lineage, 305
 invasion, 305
 spiral artery remodelling, 305
 villous structure, 305–6
 trophoblastic disease. *See* gestational
 trophoblastic disease
 TSH. *See* thyroid stimulating hormone
 tubal damage, 293, 294
 tubal pregnancy. *See* ectopic pregnancy
 tuberculosis, 288
 tuberculous salpingitis, 293
 tumour markers, 298, 299
 tumour suppressor genes, 297–8
 tumours. *See* neoplasia
 Turner syndrome, 328–30, 331
 TV. *See* tidal volume; *Trichomonas*
vaginalis
 TVS. *See* transvaginal ultrasound
 type I and II errors, 372–3
- ulceration. *See* genital ulceration
 ulipristal (Esmya®), 190, 194, 226
 ultrasound
 biophysics, 353–8
 congenital abnormality screening
 and diagnosis, 347, 348, 349
 Doppler, 356–7
 early pregnancy features, 121, 128,
 218–19
 early pregnancy problems, 123–4
 ectopic pregnancy, 133, 134,
 228
 GTD, 131, 229–30
 miscarriage, 127–8
 guidelines and recommendations for
 safe use of, 358
 MRI guidance, 362
 pregnancy dating, 120–1
 real-time B-mode, 354–6
 safety of, 357–8
 sound waves and sound wave
 generation, 353
 tissue interactions, 354
 umbilical cord, 71, 308
 unbalanced chromosome
 translocation, 340, 342
 undifferentiated uterine sarcoma, 300
 uracil, 319, 320
 ureters, 3, 87–8
 urethra, 88
 urge urinary incontinence, 183, 234,
 235–6
 urinary bladder, 69, 88
 urinary incontinence, 183, 234–6

- urinary system, physiology, 3–4, 6, 14, 15
- urinary tract infection (UTI), 3–4, 204, 233–4
- urine dipstick, 68, 69, 234
- urine output, 65, 218
- urodynamics, 235
- urogenital tract development, 117–19, 337
- uro-genital triangle, 97
- urogynaecological agents, 183
- urogynaecology
 - clinical management, 233–7
 - data interpretation, 219, 220
- uterine anomalies, 125–6
- uterine fibroids, 294
- uterine tubes of Fallopius. *See* Fallopian tubes
- uterus
 - anatomy, 90–1
 - Caesarean section incision and repair, 79
 - contractility, 8–9, 10, 266–7, 278, 279
 - decidualization changes, 303
 - involution, 8, 83
 - menstrual cycle changes, 29–31, 32–3, 120
 - neoplasms of, 299–300
 - oocyte transport to, 31
 - quiescence, 266–7, 277, 278
- UTI. *See* urinary tract infection
- vaccination
 - acquired immunity, 313
 - congenital infection prevention, 55, 56, 57, 58, 72
 - hepatitis A virus, 57, 163, 166
 - hepatitis B virus, 57, 72, 166
 - HPV, 57, 155, 298–9
- vagina
 - anatomy, 92
 - cyclical changes in, 33
 - microbiota, 310
 - neoplasms of, 302
 - sperm passage through, 40
- vaginal delivery, 81, 82, 83, 93–4
- vaginal discharge, 140
 - antibiotic treatment, 203–4
 - bacterial vaginosis, 141, 144, 145, 230–1
 - clinical management, 230–1
 - Trichomonas vaginalis*, 142–3, 144, 145, 203–4
 - vulvo-vaginal candidiasis, 141–2, 143, 144, 145, 203–4, 231
- vaginal examination, 123
- valaciclovir, 150–1
- validation studies, 385
- valproate, 80–1, 175–6
- variables, 373–4. *See also* binary variables; continuous variables
- varicella-zoster virus (VZV), 54–5
 - clinical features, 58, 59, 61
 - fetal outcomes, 60–3
 - laboratory investigations, 62–3
 - maternal outcome, 63
 - prophylaxis, 56, 57, 58
 - risk factors, 60
 - transmission, 53, 54, 55, 56, 60
 - treatment, 64
- vas deferens, 36
- vasopressin, 43, 44
- VD. *See* volume of distribution
- venous thromboembolism (VTE), 197–8
- ventilation, 2–3
- vestibule, 92, 97
- viability, ultrasound determination, 218, 219
- villi, placenta, 306
- viral hepatitis
 - A, 163, 166
 - B, 163–7
 - C, 166, 167
 - history, 139
 - immunology and antenatal screening, 317
 - investigations, 140
- viral infection. *See specific viral infections*
- vitamins
 - in breast milk, 7–8
 - C, 79–80
 - D, 269, 270
 - daily requirements, 5
 - K, 176
- voiding parameters, 235
- volatile acid, 22–3
- volume of distribution (VD), 6, 169
- vomiting. *See* nausea and vomiting
- VTE. *See* venous thromboembolism
- vulva, 97
- vulval cancer, 184, 301–2
- vulvo-vaginal candidiasis
 - altered vaginal discharge, 141–2, 143, 144, 145, 203–4, 231
 - antibiotic treatment, 203–4
 - diagnosis, 140, 142, 144
 - management, 142–3, 144
 - pregnancy complications, 145
 - recurrent candidiasis, 142
- VZV. *See* varicella-zoster virus
- warfarin, 172, 174, 176–7
- warts, anogenital, 155–6, 157, 158
- weak acid, 22
- Wolfian ducts, 337
- wound, 211–12, 289
- X-linked recessive inheritance, 332–3, 336
- X-rays
 - beam formation and detection, 359
 - biophysics, 358–63
 - clinical use, 359
 - CT, 361
 - DXA, 360
- yellow fever, 57
- Zika virus, 56, 57, 58, 59, 61–2
- zona pellucida, 40, 41, 109–10
- zygote, 40–2, 109–10